BMAL1 and neoplasm: Bmal1 and Per2 have been demonstrated to have tumor suppressor activities and alteration of their promoter methylation has been linked with poor clinical outcome and tumor progression in hematological malignancies and gliomas (Taniguchi et al., 2009; Xia et al., 2010).